Bluechiip

Executive Summary

Bluechiip provides a patented MEMS-based chip technology that enables immutable identification and real-time temperature monitoring of samples in extreme cryogenic environments, from -196°C to +100°C. Its integrated hardware—including tamper-proof chips, handheld and bulk readers, and CryoBox Tracker—coupled with the cloud-based Bluechiip Stream™ software, delivers sample-level traceability, audit trails, and compliance for biobanks, pharmaceutical R&D, clinical trials, and cold-chain logistics. By replacing traditional barcodes and manual logging, Bluechiip reduces errors, ensures sample integrity, and streamlines inventory management. The technology is particularly relevant for sensitive materials such as biological specimens, vaccines, and cell therapies that require precise temperature control and chain-of-custody documentation. Bluechiip is well-positioned in the growing biobanking and cold-chain logistics markets, driven by increasing demand for personalized medicine, cell and gene therapies, and global vaccine distribution. As a platform-stage company, it has established a commercial product suite and is actively expanding its customer base. While still a private firm, its unique value proposition in cryogenic tracking provides a defensible niche. Key growth drivers include partnerships with large biopharma organizations and logistics providers, as well as regulatory tailwinds requiring enhanced traceability. The company's ability to scale beyond its Australian base into international markets will be critical for its long-term success. Overall, Bluechiip offers a compelling solution for a critical pain point in life sciences logistics.

Upcoming Catalysts (preview)

• Q3 2026Major partnership with a top-10 pharmaceutical company for clinical trial sample tracking60% success
• Q4 2026Launch of next-generation chip with integrated multi-sensing capabilities70% success
• Q1 2027Expansion into European biobanking market via distributor agreement50% success